Brainstorm Cell Therapeutics Inc.
Returns on Capital
| Fiscal Year | ROE | ROI | ROA |
|---|---|---|---|
| FY2002 | -49.1% | -49.1% | — |
| FY2003 | -223.8% | -223.8% | — |
| FY2004 | 235.5% | 235.5% | — |
| FY2005 | -2,676.1% | -2,676.1% | — |
| FY2006 | 182.7% | 182.7% | — |
| FY2007 | 257.2% | 257.2% | — |
| FY2008 | 167.2% | 167.2% | — |
| FY2009 | 102.2% | 102.2% | — |
| FY2010 | 527.0% | 527.0% | -222.1% |
| FY2011 | -263.3% | -263.3% | -142.8% |
| FY2012 | -86.1% | -86.1% | -66.8% |
| FY2013 | -178.9% | -178.9% | -103.7% |
| FY2014 | -138.5% | -138.5% | -93.3% |
| FY2015 | -60.1% | -60.1% | -49.7% |
| FY2016 | -50.3% | -50.3% | -46.3% |
| FY2017 | -84.2% | -84.2% | -43.4% |
| FY2018 | -278.1% | -278.1% | -124.2% |
| FY2019 | 190.2% | 190.2% | -355.9% |
| FY2020 | -89.7% | -89.7% | -62.1% |
| FY2021 | -126.4% | -126.4% | -83.5% |
| FY2022 | 805.2% | 805.2% | -287.3% |
| FY2023 | 353.9% | 353.9% | -408.6% |
| FY2024 | 149.7% | 149.7% | -634.4% |
| FY2025 | 103.2% | 103.2% | -1,008.5% |